Effects of monomeric acrylic embedding media on the antigenicity of two epitopes of the MIC2-encoded Ewing's sarcoma cell membrane antigen

Osteosarcoma and Ewing’s sarcoma are the most common malignant bone tumors. Conventional therapies such as polychemotherapy, local surgery, and radiotherapy improve the clinical outcome for patients. However, they are accompanied by acute and chronic side effects that affect the quality of life of patients, motivating novel research lines on therapeutic options for the treatment of sarcomas. Previous experimental work with physical plasma operated at body temperature (cold atmospheric plasma, CAP) demonstrated anti-oncogenic effects on different cancer cell types. This study investigated the anti-cancer effect of CAP on two bone sarcoma entities, osteosarcoma and Ewing’s sarcoma, which were represented by four cell lines (U2-OS, MNNG/HOS, A673, and RD-ES). A time-dependent anti-proliferative effect of CAP on all cell lines was observed. CAP-induced alterations in cell membrane functionality were detected by performing a fluorescein diacetate (FDA) release assay and an ATP release assay. Additionally, modifications of the cell membrane and modifications in the actin cytoskeleton composition were examined using fluorescence microscopy monitoring dextran-uptake assay and G-/F-actin distribution. Furthermore, the CAP-induced induction of apoptosis was determined by TUNEL and active caspases assays. The observations suggest that a single CAP treatment of bone sarcoma cells may have significant anti-oncogenic effects and thus may be a promising extension to existing applications.

Download Full-text

Cytogenetics of a Ewing's sarcoma cell line

Cancer Genetics and Cytogenetics ◽

10.1016/0165-4608(86)90394-8 ◽

1986 ◽

Vol 19 (1-2) ◽

pp. 182

Keyword(s):

Cell Line ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Sarcoma Cell ◽

Sarcoma Cell Line

Download Full-text

Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing’s sarcoma cell lines

Journal of Neurochemistry ◽

10.1111/j.1471-4159.2007.04835.x ◽

2007 ◽

Vol 103 (4) ◽

pp. 1344-1354 ◽

Cited By ~ 40

Author(s):

Cristina Zanini ◽

Giuliana Giribaldi ◽

Giorgia Mandili ◽

Franco Carta ◽

Nicoletta Crescenzio ◽

...

Keyword(s):

Heat Shock ◽

Heat Shock Proteins ◽

Cell Lines ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Sarcoma Cell ◽

Shock Proteins

Download Full-text

Discovery and Validation of a Compound to Target Ewing’s Sarcoma

Pharmaceutics ◽

10.3390/pharmaceutics13101553 ◽

2021 ◽

Vol 13 (10) ◽

pp. 1553

Author(s):

Ellie Esfandiari Nazzaro ◽

Fahad Y. Sabei ◽

Walter K. Vogel ◽

Mohamad Nazari ◽

Katelyn S. Nicholson ◽

...

Keyword(s):

Cell Lines ◽

Ewing’S Sarcoma ◽

Ewing's Sarcoma ◽

Apoptotic Cell ◽

Intensive Therapy ◽

Xenograft Model ◽

Chemotherapeutic Agents ◽

Cytotoxic Agents ◽

Sarcoma Cell

Ewing’s sarcoma, characterized by pathognomonic t (11; 22) (q24; q12) and related chromosomal ETS family translocations, is a rare aggressive cancer of bone and soft tissue. Current protocols that include cytotoxic chemotherapeutic agents effectively treat localized disease; however, these aggressive therapies may result in treatment-related morbidities including second-site cancers in survivors. Moreover, the five-year survival rate in patients with relapsed, recurrent, or metastatic disease is less than 30%, despite intensive therapy with these cytotoxic agents. By using high-throughput phenotypic screening of small molecule libraries, we identified a previously uncharacterized compound (ML111) that inhibited in vitro proliferation of six established Ewing’s sarcoma cell lines with nanomolar potency. Proteomic studies show that ML111 treatment induced prometaphase arrest followed by rapid caspase-dependent apoptotic cell death in Ewing’s sarcoma cell lines. ML111, delivered via methoxypoly(ethylene glycol)-polycaprolactone copolymer nanoparticles, induced dose-dependent inhibition of Ewing’s sarcoma tumor growth in a murine xenograft model and invoked prometaphase arrest in vivo, consistent with in vitro data. These results suggest that ML111 represents a promising new drug lead for further preclinical studies and is a potential clinical development for the treatment of Ewing’s sarcoma.

Download Full-text